These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 37489294)

  • 41. TRIM29 regulates the SETBP1/SET/PP2A axis via transcription factor VEZF1 to promote progression of ovarian cancer.
    Qiao HY; Zhang Q; Wang JM; Jiang JY; Huyan LY; Yan J; Li C; Wang HQ
    Cancer Lett; 2022 Mar; 529():85-99. PubMed ID: 34973391
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Spectrum of NSD1 mutations in Sotos and Weaver syndromes.
    Rio M; Clech L; Amiel J; Faivre L; Lyonnet S; Le Merrer M; Odent S; Lacombe D; Edery P; Brauner R; Raoul O; Gosset P; Prieur M; Vekemans M; Munnich A; Colleaux L; Cormier-Daire V
    J Med Genet; 2003 Jun; 40(6):436-40. PubMed ID: 12807965
    [TBL] [Abstract][Full Text] [Related]  

  • 43.
    Coccaro N; Tota G; Zagaria A; Anelli L; Specchia G; Albano F
    Oncotarget; 2017 Aug; 8(31):51920-51935. PubMed ID: 28881700
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical delineation of SETBP1 haploinsufficiency disorder.
    Jansen NA; Braden RO; Srivastava S; Otness EF; Lesca G; Rossi M; Nizon M; Bernier RA; Quelin C; van Haeringen A; Kleefstra T; Wong MMK; Whalen S; Fisher SE; Morgan AT; van Bon BW
    Eur J Hum Genet; 2021 Aug; 29(8):1198-1205. PubMed ID: 33867525
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Putative Roles of SETBP1 Dosage on the SET Oncogene to Affect Brain Development.
    Antonyan L; Ernst C
    Front Neurosci; 2022; 16():813430. PubMed ID: 35685777
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cell-type-specific gene expression and regulation in the cerebral cortex and kidney of atypical Setbp1
    Whitlock JH; Soelter TM; Howton TC; Wilk EJ; Oza VH; Lasseigne BN
    J Cell Mol Med; 2023 Nov; 27(22):3565-3577. PubMed ID: 37872881
    [TBL] [Abstract][Full Text] [Related]  

  • 47. SETBP1 is dispensable for normal and malignant hematopoiesis.
    Tanaka A; Nishimura K; Saika W; Kon A; Koike Y; Tatsumi H; Takeda J; Nomura M; Zang W; Nakayama M; Matsuda M; Yamazaki H; Fukumoto M; Ito H; Hayashi Y; Kitamura T; Kawamoto H; Takaori-Kondo A; Koseki H; Ogawa S; Inoue D
    Leukemia; 2023 Sep; 37(9):1802-1811. PubMed ID: 37464069
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prenatal diagnosis and molecular cytogenetic characterization of an inherited microdeletion of 18q12.3 encompassing SETBP1.
    Zhou Y; Quan Y; Wu Y; Zhang Y
    J Int Med Res; 2022 Sep; 50(9):3000605221121955. PubMed ID: 36113068
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Recommendations for Cancer Surveillance in Individuals with RASopathies and Other Rare Genetic Conditions with Increased Cancer Risk.
    Villani A; Greer MC; Kalish JM; Nakagawara A; Nathanson KL; Pajtler KW; Pfister SM; Walsh MF; Wasserman JD; Zelley K; Kratz CP
    Clin Cancer Res; 2017 Jun; 23(12):e83-e90. PubMed ID: 28620009
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Correlation of myelodysplastic syndromes with i(17)(q10) and TP53 and SETBP1 mutations.
    Adema V; Larráyoz MJ; Calasanz MJ; Palomo L; Patiño-García A; Agirre X; Hernández-Rivas JM; Lumbreras E; Buño I; Martinez-Laperche C; Mallo M; García O; Álvarez S; Blazquez B; Cervera J; Luño E; Valiente A; Vallespí MT; Arenillas L; Collado R; Pérez-Oteyza J; Solé F
    Br J Haematol; 2015 Oct; 171(1):137-41. PubMed ID: 25716545
    [No Abstract]   [Full Text] [Related]  

  • 51. Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia.
    Stieglitz E; Troup CB; Gelston LC; Haliburton J; Chow ED; Yu KB; Akutagawa J; Taylor-Weiner AN; Liu YL; Wang YD; Beckman K; Emanuel PD; Braun BS; Abate A; Gerbing RB; Alonzo TA; Loh ML
    Blood; 2015 Jan; 125(3):516-24. PubMed ID: 25395418
    [TBL] [Abstract][Full Text] [Related]  

  • 52. SETBP1 mutations in juvenile myelomonocytic leukaemia and myelodysplastic syndrome but not in paediatric acute myeloid leukaemia.
    Shiba N; Ohki K; Park MJ; Sotomatsu M; Kudo K; Ito E; Sako M; Arakawa H; Hayashi Y
    Br J Haematol; 2014 Jan; 164(1):156-9. PubMed ID: 24117422
    [No Abstract]   [Full Text] [Related]  

  • 53. Detection of a novel
    Yang H; Liu Z; Chen D; Lin W; Wang L; Chen T; Wang R; Yan X
    Front Pediatr; 2022; 10():920741. PubMed ID: 36147799
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mutant SETBP1 enhances NRAS-driven MAPK pathway activation to promote aggressive leukemia.
    Carratt SA; Braun TP; Coblentz C; Schonrock Z; Callahan R; Curtiss BM; Maloney L; Foley AC; Maxson JE
    Leukemia; 2021 Dec; 35(12):3594-3599. PubMed ID: 34002029
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Weaver syndrome and EZH2 mutations: Clarifying the clinical phenotype.
    Tatton-Brown K; Murray A; Hanks S; Douglas J; Armstrong R; Banka S; Bird LM; Clericuzio CL; Cormier-Daire V; Cushing T; Flinter F; Jacquemont ML; Joss S; Kinning E; Lynch SA; Magee A; McConnell V; Medeira A; Ozono K; Patton M; Rankin J; Shears D; Simon M; Splitt M; Strenger V; Stuurman K; Taylor C; Titheradge H; Van Maldergem L; Temple IK; Cole T; Seal S; ; Rahman N
    Am J Med Genet A; 2013 Dec; 161A(12):2972-80. PubMed ID: 24214728
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CSF3R T618I, SETBP1 G870S, SRSF2 P95H, and ASXL1 Q780* tetramutation co-contribute to myeloblast transformation in a chronic neutrophilic leukemia.
    Qian Y; Chen Y; Li X
    Ann Hematol; 2021 Jun; 100(6):1459-1461. PubMed ID: 33822276
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Molecular characterization of atypical chronic myeloid leukemia and chronic neutrophilic leukemia].
    Senín A; Arenillas L; Martínez-Avilés L; Fernández-Rodríguez C; Bellosillo B; Florensa L; Besses C; Álvarez-Larrán A
    Med Clin (Barc); 2015 Jun; 144(11):487-90. PubMed ID: 24854193
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia: a report from the Italian AIEOP study group.
    Bresolin S; De Filippi P; Vendemini F; D'Alia M; Zecca M; Meyer LH; Danesino C; Locatelli F; Masetti R; Basso G; Te Kronnie G
    Oncotarget; 2016 May; 7(20):28914-9. PubMed ID: 26980750
    [TBL] [Abstract][Full Text] [Related]  

  • 59. ASXL1 and SETBP1 mutations promote leukaemogenesis by repressing TGFβ pathway genes through histone deacetylation.
    Saika M; Inoue D; Nagase R; Sato N; Tsuchiya A; Yabushita T; Kitamura T; Goyama S
    Sci Rep; 2018 Oct; 8(1):15873. PubMed ID: 30367089
    [TBL] [Abstract][Full Text] [Related]  

  • 60. SETBP1 mutation determines sensitivity to immune checkpoint inhibitors in melanoma and NSCLC.
    An F; Zhang W; Guo Y; Shi F; Kong Y; Tang L; Han C; Wang Q
    Aging (Albany NY); 2023 Aug; 15(15):7476-7495. PubMed ID: 37535001
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.